Qi xiangtengda: routine maintenance of 100000 t / a methyl ethyl ketone unit
Qixiang Tengda announced that the 100000 t / a methyl ethyl ketone unit was subject to routine maintenance. Qi Xiang Tengda introduced that the operation of methyl ethyl ketone unit and the service life of catalyst in Zibo headquarters of the company have reached the upper limit of the cycle. The company plans to start shutdown and maintenance on August 10. It is estimated that the shutdown and maintenance time will be 35 days, which will not have a great impact on the completion of the company's annual production and operation plan and operating performance.
This text is a result of machine translation.
Related companies：
Briefing Jun 28, 2022 11:10 AM
· Automotive
GAC group released a new generation of microcrystalline technology, and the volume energy density of super energy iron lithium battery increased by 20%
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Jan 06, 2023 08:30 AM
Nov 16, 2022 05:19 PM
Nov 08, 2022 08:32 AM
Nov 07, 2022 04:27 PM
Briefing Jun 13, 2022 09:44 AM
· Healthcare
Cro plate fell, and Wuxi apptec fell nearly 10%
Healthcare
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Healthcare, Financials
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
See more
Read next
Insight
In-depth
Insight
In-depth